期刊
ACTA DERMATO-VENEREOLOGICA
卷 96, 期 4, 页码 464-467出版社
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-2264
关键词
Sezary syndrome; marker; CD164
类别
资金
- Swiss National Cancer Foundation [PMPDP3_151326]
- Forschungskredit of the University of Zurich [FK-14-032]
- Sciex-NMS Programme [14.111]
- Helmut Horten Foundation, Switzerland
Sezary syndrome is a primary cutaneous T-cell lymphoma characterized by pruritic erythroderma, peripheral lymphadenopathy and the presence of malignant T cells in the blood. Unequivocal detection of malignant cells in patients with Sezary syndrome is of important diagnostic, prognostic and therapeutic value. However, no single Sezary syndrome specific cell surface marker has been identified. In a cohort of patients with Sezary syndrome, CD164 expression on total CD4(+) lymphocytes was significantly upregulated compared with healthy controls. CD164 expression was in most cases limited to CD44(+)CD26(-) malignant T lymphocytes, unequivocally identified using flow-cytometry by the expression of a specific VD clone for each patient. Increased expression of CD164 may be a promising diagnostic parameter and a potential target for a CD164-linked therapeutic approach in Sezary syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据